T cell selection and differential activation on structurally related HLA-DR4 ligands.
Plasticity of TCR interactions during CD4(+) T cell activation by an MHC-peptide complex accommodates variation in the peptide or MHC contact sites in which recognition of an altered ligand by the T cell can modify the T cell response. To explore the contribution of this form of TCR cross-recognition in the context of T cell selection on disease-associated HLA molecules, we have analyzed the relationship between TCR recognition of the DRB1*0401- and DRB1*0404-encoded HLA class II molecules associated with rheumatoid arthritis. Thymic reaggregation cultures demonstrated that CD4(+) T cells selected on either DRB1*0401 or DRB1*0404 could be subsequently activated by the other MHC molecule. Using HLA tetramer technology we identify hemagglutinin residue 307-319-specific T cells restricted by DRB1*0401, but activated by hemagglutinin residues 307-319, in the context of DRB1*0404. One such clone exhibits an altered cytokine profile upon activation with the alternative MHC ligand. This altered phenotype persists when both class II molecules are present. These findings directly demonstrate that T cells selected on an MHC class II molecule carry the potential for activation on altered self ligands when encountering Ags presented on a related class II molecule. In individuals heterozygous for these alleles the possibility of TCR cross-recognition could lead to an aberrant immune response.
Gebe
J A
JA
Benaroya Research Institute, Virginia Mason Research Center, Seattle, WA 98101, USA.
Novak
E J
EJ
Kwok
W W
WW
Farr
A G
AG
Nepom
G T
GT
Buckner
J H
JH
D000818:Animals; D017951:Antigen Presentation; D001172:Arthritis, Rheumatoid / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D001704:Biopolymers; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002454:Cell Differentiation; D002460:Cell Line; D002478:Cells, Cultured; D017637:Clonal Deletion; D000939:Epitopes / Q000276:immunology; D005838:Genotype; D006684:HLA-DR Antigens / Q000276:immunology; D015804:HLA-DR4 Antigen / Q000737:chemistry / Q000276:immunology*; D059811:HLA-DRB1 Chains; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000378:metabolism; D046911:Macromolecular Substances; D051379:Mice; D010446:Peptide Fragments / Q000276:immunology; D010641:Phenotype; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D017634:Self Tolerance / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014162:Transfection; D001613:beta 2-Microglobulin / Q000172:deficiency / Q000235:genetics
D001704:Biopolymers; D000939:Epitopes; D006684:HLA-DR Antigens; D015804:HLA-DR4 Antigen; D059811:HLA-DRB1 Chains; C553505:HLA-DRB1*04:01 antigen; D000949:Histocompatibility Antigens Class II; D008024:Ligands; D008222:Lymphokines; D046911:Macromolecular Substances; D010446:Peptide Fragments; D011948:Receptors, Antigen, T-Cell; D001613:beta 2-Microglobulin